Methergine and Fatigue - a phase IV clinical study of FDA data

Summary:

Fatigue is reported as a side effect among people who take Methergine (methylergonovine maleate), especially for people who are female, 0-1 old, have been taking the drug for < 1 month also take Flexeril, and have Postpartum haemorrhage.

The phase IV clinical study analyzes which people have Fatigue when taking Methergine. It is created by eHealthMe based on reports of 957 people who have side effects when taking Methergine from the FDA, and is updated regularly.

What is Methergine?

Methergine has active ingredients of methylergonovine maleate. It is often used in migraine. eHealthMe is studying from 999 Methergine users. Check the latest studies of Methergine.

What is Fatigue?

Fatigue (feeling of tiredness) is found to be associated with 4,027 drugs and 6,380 conditions by eHealthMe. Check the latest studies of Fatigue.

On Jul, 28, 2026

957 people reported to have side effects when taking Methergine.
Among them, 27 people (2.82%) have Fatigue.

Among these 27 people:

How long have people been on Methergine when they have Fatigue? *

What is the gender of people who have Fatigue when taking Methergine? *

female: 96 %
male: 4 %

What is the age of people who have Fatigue when taking Methergine? *

What are other drugs people take besides Methergine? *

What are other side effects people have besides Fatigue? *

Appetite Disorder (abnormal eating habits): 11 people, 40.74%
Hypotension (abnormally low blood pressure): 10 people, 37.04%
Tonic Convulsion (the person will quickly lose consciousness and the skeletal muscles will suddenly tense, often causing the extremities to be pulled towards the body or rigidly pushed away from it): 7 people, 25.93%
Peripheral Vascular Disorder: 6 people, 22.22%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 18.52%
Skin Discoloration - Bluish (bluish colour of skin): 5 people, 18.52%
Nausea (feeling of having an urge to vomit): 4 people, 14.81%
Stress And Anxiety: 4 people, 14.81%
Hyperhidrosis (abnormally increased sweating): 4 people, 14.81%
Oedema Peripheral (superficial swelling): 4 people, 14.81%

What are the existing conditions these people have? *

Postpartum Haemorrhage (bleeding in woman after she has given birth): 2 people, 7.41%
Uterine Atony (failure of the uterus to contract following delivery): 1 person, 3.70%
Pain: 1 person, 3.70%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 3.70%
Nausea (feeling of having an urge to vomit): 1 person, 3.70%
Haemorrhage (bleeding): 1 person, 3.70%
Gastric Ulcer (stomach ulcer): 1 person, 3.70%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 3.70%
Cystitis Interstitial (unknown cause characterized by bladder pain): 1 person, 3.70%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Methergine and have Fatigue?

- Check whether Fatigue is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Methergine:

Methergine (999 reports)

Fatigue treatments and more:

Fatigue (967,537 reports)

Browse all side effects of Methergine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fatigue:

Fatigue (4,027 drugs)

Browse all the conditions that are associated with Fatigue:

Fatigue (6,380 conditions)

Related publications that referenced our studies

Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W, "A randomized controlled trial of coenzyme Q 10 for fatigue in the late-onset sequelae of poliomyelitis", Complementary therapies in medicine, 2015 Dec .
Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W, "A randomized controlled trial of coenzyme Q 10 for fatigue in the late-onset sequelae of poliomyelitis", Complementary therapies in medicine, 2015 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on methylergonovine maleate (the active ingredients of Methergine) and Methergine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.